Equity Overview
Price & Market Data
Price: $2.91
Daily Change: +$0.055 / 1.89%
Daily Range: $2.85 - $2.97
Market Cap: $27,534,248
Daily Volume: 15,069
Performance Metrics
1 Week: -8.18%
1 Month: -26.63%
3 Months: -25.70%
6 Months: -92.73%
1 Year: -79.93%
YTD: -32.09%
Company Details
Employees: 12
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.